Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (827)	4/20/1999 10:34:00 PM
From: Miljenko Zuanic	Respond to of 1073

<<Miljenko: We have no conflict to be concerned with now. We have had some disagreements in the past, but they are old history. Anyone who has earned Rick Harmon's respect has mine as well. >> Dr. Tracy, this is valid both way. Thanks for respond. I am not wary about competition, at this time. I am trying to understand, and to explain to myself, why NBIX (and whole neuro-sector: SNAP, SIBI, NRGN, GLIA,...) is at lower level ever? Why is CRFr program at NBIX (as well as other programs) neglected by investment community? So, if other comps (specially pharmas) have active CRF programs maybe street will discover hidden value. I understand that PI results has little value for general investors and that current PII trial is to test doses range (which were found safe in PI trials) in real world. I do not have any info from this PI trials, so I thought maybe PI results didn't satisfied NBIX shareholders (why will anyone sell at this price?). I guess answer is in lost patience. Hope after successful PII trials things will change for better. Miljenko